SlideShare uma empresa Scribd logo
1 de 36
LIVER CANCER
PRANAV THAZHE VEETTIL KARKKDAYIL
GROUP NO.4
DEPT OF SURGERY
TSMU
• Liver cancers are of 2 types
BENIGN
MALIGNANT
Benign Tumor Include
1) Hepatic Hemangioma
2) Focus Nodular Hyperplasia (F.N.H)
3) Hepatic Adenoma
HEPATIC HEMANGIOMA
• Most common benign tumor
• Womens are effected
• Clinical features:
Mostly asymptomatic
Symptomatic (abdominal discomfort)
• Kassabach Meritt Syndrome: Associated with consumptive
coagulopathy with low platelet count
Both FNAC and biopsy– contra indication due to bleeding
• IOC- MRI
• Treatment – Growth of hemangioma occurs by
ectasia not neoplasia
• Treatment of choice ENUCLETION
Focus Nodular Hyperplasia (F.N.H)
• Females due to oral contraceptive pills
• Second most common benign tumor of liver
• CECT – Central stellate scar
• Angiogram –CART WHEEL /SPOKE WHEEL
• Treatment – not required
Hepatic Adenoma
• Benign proliferation of hepatocytes
• Strongly associated with oral contraceptive pills
• Associated with increased risk of hemorrhage
and tumor
MALIGNANT TUMORS OF LIVER
• HEPATOCELLULAR CARCINOMA
• CHOLANGIOCARCINOMA
• HEPATOBLASTOMA
• HEPTIC ANGIOSARCOMA
HEPATOCELLULAR CARCINOMA
• Hepatocellular carcinoma (HCC) is the most common
type of primary liver cancer.
• Hepatocellular carcinoma occurs most often in people
with chronic liver diseases, such as cirrhosis caused by
hepatitis B or hepatitis C infection
• Most common primary malignancy of the liver.
Geographical distribution is clearly related to the
incidence of Hepatitis B infection.
• The highest incidence in - Southeast Asia and Tropical
Africa. The lowest incidence in - Australia, North
America and Europe. Epidemiologic evidence strongly
suggests that HCC is largely related to environmental
factors
• HCC is two to eight times more common in
males compared with females in low- and high-
incidence areas.
• The higher incidence in males is probably
related to higher rates of associated risk factors.
HBV infection,
• Cirrhosis,
• Smoking, Alcohol abuse, and
• Higher hepatic DNA synthesis in cirrhosis
Infections
• Hepatitis B virus
• Hepatitis C virus
• Cirrhosis Alcohol induced
• Autoimmune hepatitis
• Primary biliary cirrhosis
Environmental
• Aflatoxins
• Pyrrolizidine
Metabolicdiseases
• Hemochromatosis
• Alpha1-antitrypsin deficiency
• Wilson's disease Porphyria cutanea tarda
• Type 1 and 3 glycogen storage disease
• Galactosemia Citrullinemia Hereditary
tyrosinemia
• Familial cholestatic cirrhosis
CLINICAL FEATURES
• Most commonly, patients presenting with HCC
are men 50 to 60 years of age who complain of
right upper quadrant abdominal pain and weight
loss, and have a palpable mass.
• In countries endemic for HBV, presentation at a
younger age is common and probably related to
childhood infection
• Unfortunately, in unscreened populations, HCC
tends to present at a later stage because of the
lack of symptoms in early stages.
• Presentation at an advanced stage is often with
vague right upper quadrant abdominal pain that
sometimes radiates to the right shoulder.
• Nonspecific symptoms of advanced malignancy
such as anorexia, nausea, lethargy, and weight
loss are also common
• Another common presentation of HCC is hepatic
decompensation in a patient with known mild
cirrhosis or even in patients with unrecognized
cirrhosis.
• HCC can rarely present as a rupture, with the
sudden onset of abdominal pain followed by
hypovolemic shock secondary to intraperitoneal
bleeding
diagnosis
• Diagnosis is often confirmed with a biopsy
Diagnosis can sometimes be confirmed with blood or
imaging tests
• Physical examination
• Blood test for alpha-fetoprotein (AFP); 50%-70% of
people with primary liver cancer have elevated levels
• Ultrasound of the abdomen Computed tomography
(CT or CAT) scan
• Magnetic resonance imaging (MRI)
• AFP measurements can be helpful in the
diagnosis of HCC. An AFP level higher than
20 ng/mL is noted in approximately 75% of
documented cases of HCC.
• Radiologic investigation is a critical part of the diagnosis
of HCC. Ultrasound plays a significant role in screening
and early detection of HCC, but definitive diagnosis and
treatment planning rely on CT and/or MRI.
• Contrast-enhanced CT and MRI protocols aimed at
diagnosing HCC take advantage of the hypervascularity
of these tumors, and arterial phase images are critical to
assess the extent of disease adequately
• CT and MRI also evaluate the extent of disease
in terms of peritoneal metastases, nodal
metastases, and extent of vascular and biliary
involvement.
• Detection of bland or tumor thrombus in the
portal or hepatic venous system is also
important and can be diagnosed with any of
these modalities.
• If atypical features appear on imaging, a biopsy should
be obtained for histologic diagnosis.
• For hepatic nodules larger than 2 cm, a triplephase CT or
MRI scan is required if typical features of HCC are
identified in combination with an AFP level higher than
200 ng/mL.
• If typical features appear on imaging, the diagnosis of
HCC is confirmed.
• If atypical features are seen, then biopsy is required to
confirm the histologic diagnosis.
TNM GRADING
• T1 :solitory tumour 2cm without vascular
invasion
T1a : Solitary tumor <2 cm
T1b :Solitary tumor >2 cm without vascular invasion
T2 :Solitary tumor >2 cm with vascular invasion; or multiple
tumors, none <5 cm
• T3: Multiple tumors, at least one of which is >5 cm
• T4 :Single tumor or tumors of any size involving a major
branch of the portal vein or hepatic vein, or tumor(s) with
direct invasion of adjacent organs other than the gallbladder
or with perforation of visceral peritoneum
Regional lymph nodes (N)
NX:Regional lymph nodes cannot be assessed
• N0: No regional lymph node metastasis
• N1: Regional lymph node metastasiS
• METASTASIS
• Mo :NO distant metastasis
• M1:Distant Metastasis
treatment
• 1.Resection of right and left lobe
:Hemipectotomy
• 2.Trans arterial embolization
• 3.Partiation of liver
• 4.liver transplantation: we follow Millams
criteria
a)size of tumor <5cm
b) multiple tumor size <3cm and no. 2-3
c) no extrahepatic or vascular spread
CHOLANGIOCARCINOMA
• Malignancy of bile duct epithelium
• Usually in older patients
TYPES OF CHOLANGIOCARCINOMA
• INTRA HEPATIC - those starting within the
liver
• PRE HEPATIC – Bile duct cancer starting in the
hilum
• DISTSAL BILE DUCT CANCER – those satrting
from down.
RISK FACTOR
• Primary cholangitis
• Ulcerative colitis
• Cirrohsis
• HBV,HCV,HIV toxins
• Diabetes Mellitus
MOST COMMON SITE- HILUM- KLASTIN
TUMOR
• TUMOR MARKERS- CAG-G, CEA
HISTOLOGICAL
• Diffuse,infiltrate/sclerosinng (worst prognosis)
• Nodular/mass forming
• Papillary( Best prognosis)
CLINICAL FEATURES
• Painless progressive jaundice
• Fatigue
• Anorexia
• Clay coloured stools
INVESTIGATION
• Lab investigation
• Tumor markers- CEAX,CA19-9
• USG
• CT
• MRI + MRCP (ioc)
MRI IMAGE OF
INTRAHEPATIC
CHOLANGIOCARCINOMA
• MRI IMAGE OF HILAR
CHOLANGIOCARCINOMA
BISMUTH-CORELELLE CLASSIFICATION
BISMUTH-CORELELLE CLASSIFICATION
TREATMENT
• Hilar cholangiocarcinoma:
CBD Resection +lymphadenctomy+caudate lobectomy
Distal cholangiocarcinoma
:Pyrolous sparing Whipples Procedure
Liver cancer

Mais conteúdo relacionado

Mais procurados

Cystic diseases of kidney
Cystic diseases of kidneyCystic diseases of kidney
Cystic diseases of kidney
essamramdan
 

Mais procurados (20)

Gall bladder carcinoma
Gall bladder carcinomaGall bladder carcinoma
Gall bladder carcinoma
 
Cystic diseases of kidney
Cystic diseases of kidneyCystic diseases of kidney
Cystic diseases of kidney
 
Choledocholithiasis
CholedocholithiasisCholedocholithiasis
Choledocholithiasis
 
Hepatocellular carcinoma
Hepatocellular  carcinomaHepatocellular  carcinoma
Hepatocellular carcinoma
 
Cancer of Pancreas
 Cancer of Pancreas Cancer of Pancreas
Cancer of Pancreas
 
Gallblader carcinoma
Gallblader carcinomaGallblader carcinoma
Gallblader carcinoma
 
Renal cell carcinoma
Renal cell carcinomaRenal cell carcinoma
Renal cell carcinoma
 
Renal cell carcinoma
Renal cell carcinomaRenal cell carcinoma
Renal cell carcinoma
 
Pancreatic cancer
Pancreatic cancerPancreatic cancer
Pancreatic cancer
 
Carcinoma gall bladder
Carcinoma gall bladderCarcinoma gall bladder
Carcinoma gall bladder
 
CA Prostate
CA ProstateCA Prostate
CA Prostate
 
Tumors of the kidney
Tumors of the kidneyTumors of the kidney
Tumors of the kidney
 
Prostate cancer
Prostate cancerProstate cancer
Prostate cancer
 
Pancreatic cancer
Pancreatic cancerPancreatic cancer
Pancreatic cancer
 
Bladder carcinoma
Bladder carcinomaBladder carcinoma
Bladder carcinoma
 
Urinary bladder carcinoma
Urinary bladder carcinoma Urinary bladder carcinoma
Urinary bladder carcinoma
 
Colon cancer
Colon cancerColon cancer
Colon cancer
 
Cystic tumours of pancreas
Cystic tumours of pancreasCystic tumours of pancreas
Cystic tumours of pancreas
 
Hepatocellular carcinoma final
Hepatocellular carcinoma finalHepatocellular carcinoma final
Hepatocellular carcinoma final
 
Pancreatic carcinoma
Pancreatic carcinomaPancreatic carcinoma
Pancreatic carcinoma
 

Semelhante a Liver cancer

Esophageal Carcinoma
Esophageal CarcinomaEsophageal Carcinoma
Esophageal Carcinoma
bbxoxo
 

Semelhante a Liver cancer (20)

Liver lesions benign and malignant and treatment options.pptx
Liver lesions benign and malignant and treatment options.pptxLiver lesions benign and malignant and treatment options.pptx
Liver lesions benign and malignant and treatment options.pptx
 
Colorectal cancer.pptx by -MANOJIT(MS)
Colorectal cancer.pptx by -MANOJIT(MS)Colorectal cancer.pptx by -MANOJIT(MS)
Colorectal cancer.pptx by -MANOJIT(MS)
 
Hepatocellular carcinomas
Hepatocellular carcinomasHepatocellular carcinomas
Hepatocellular carcinomas
 
Liver tomour
Liver tomourLiver tomour
Liver tomour
 
livertomour-170928174535.pdf
livertomour-170928174535.pdflivertomour-170928174535.pdf
livertomour-170928174535.pdf
 
Benign neoplasms of liver
Benign neoplasms of liverBenign neoplasms of liver
Benign neoplasms of liver
 
Tumors of kidney and Bladder by Sunil Kumar Daha
Tumors of kidney and Bladder by Sunil Kumar DahaTumors of kidney and Bladder by Sunil Kumar Daha
Tumors of kidney and Bladder by Sunil Kumar Daha
 
Paediatric abdominal masses
Paediatric abdominal massesPaediatric abdominal masses
Paediatric abdominal masses
 
Liver hemangiona
Liver hemangionaLiver hemangiona
Liver hemangiona
 
Hcc
HccHcc
Hcc
 
GIT malignancies
GIT malignanciesGIT malignancies
GIT malignancies
 
Urologic malignancy
Urologic malignancyUrologic malignancy
Urologic malignancy
 
Carcinoma Rectum by Dr.K.AmrithaAnilkumar
Carcinoma Rectum by Dr.K.AmrithaAnilkumarCarcinoma Rectum by Dr.K.AmrithaAnilkumar
Carcinoma Rectum by Dr.K.AmrithaAnilkumar
 
Hepatocellularcarcinoma 23-6-2016
Hepatocellularcarcinoma  23-6-2016Hepatocellularcarcinoma  23-6-2016
Hepatocellularcarcinoma 23-6-2016
 
Esophageal Carcinoma
Esophageal CarcinomaEsophageal Carcinoma
Esophageal Carcinoma
 
management of Liver cancers
management of Liver cancersmanagement of Liver cancers
management of Liver cancers
 
Hepatocellular Carcinoma and Gall Bladder Carcinoma
Hepatocellular Carcinoma and Gall Bladder CarcinomaHepatocellular Carcinoma and Gall Bladder Carcinoma
Hepatocellular Carcinoma and Gall Bladder Carcinoma
 
Carcinoma gallbladder.
Carcinoma gallbladder.Carcinoma gallbladder.
Carcinoma gallbladder.
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinoma
 
Testicular tumour/ case history
Testicular tumour/ case history Testicular tumour/ case history
Testicular tumour/ case history
 

Último

Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
ZurliaSoop
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
negromaestrong
 

Último (20)

Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Magic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxMagic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 

Liver cancer

  • 1. LIVER CANCER PRANAV THAZHE VEETTIL KARKKDAYIL GROUP NO.4 DEPT OF SURGERY TSMU
  • 2. • Liver cancers are of 2 types BENIGN MALIGNANT Benign Tumor Include 1) Hepatic Hemangioma 2) Focus Nodular Hyperplasia (F.N.H) 3) Hepatic Adenoma
  • 3. HEPATIC HEMANGIOMA • Most common benign tumor • Womens are effected • Clinical features: Mostly asymptomatic Symptomatic (abdominal discomfort) • Kassabach Meritt Syndrome: Associated with consumptive coagulopathy with low platelet count Both FNAC and biopsy– contra indication due to bleeding • IOC- MRI
  • 4. • Treatment – Growth of hemangioma occurs by ectasia not neoplasia • Treatment of choice ENUCLETION
  • 5. Focus Nodular Hyperplasia (F.N.H) • Females due to oral contraceptive pills • Second most common benign tumor of liver • CECT – Central stellate scar • Angiogram –CART WHEEL /SPOKE WHEEL • Treatment – not required
  • 6. Hepatic Adenoma • Benign proliferation of hepatocytes • Strongly associated with oral contraceptive pills • Associated with increased risk of hemorrhage and tumor
  • 7. MALIGNANT TUMORS OF LIVER • HEPATOCELLULAR CARCINOMA • CHOLANGIOCARCINOMA • HEPATOBLASTOMA • HEPTIC ANGIOSARCOMA
  • 8. HEPATOCELLULAR CARCINOMA • Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. • Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection
  • 9. • Most common primary malignancy of the liver. Geographical distribution is clearly related to the incidence of Hepatitis B infection. • The highest incidence in - Southeast Asia and Tropical Africa. The lowest incidence in - Australia, North America and Europe. Epidemiologic evidence strongly suggests that HCC is largely related to environmental factors
  • 10. • HCC is two to eight times more common in males compared with females in low- and high- incidence areas.
  • 11. • The higher incidence in males is probably related to higher rates of associated risk factors. HBV infection, • Cirrhosis, • Smoking, Alcohol abuse, and • Higher hepatic DNA synthesis in cirrhosis
  • 12. Infections • Hepatitis B virus • Hepatitis C virus • Cirrhosis Alcohol induced • Autoimmune hepatitis • Primary biliary cirrhosis Environmental • Aflatoxins • Pyrrolizidine
  • 13. Metabolicdiseases • Hemochromatosis • Alpha1-antitrypsin deficiency • Wilson's disease Porphyria cutanea tarda • Type 1 and 3 glycogen storage disease • Galactosemia Citrullinemia Hereditary tyrosinemia • Familial cholestatic cirrhosis
  • 14. CLINICAL FEATURES • Most commonly, patients presenting with HCC are men 50 to 60 years of age who complain of right upper quadrant abdominal pain and weight loss, and have a palpable mass. • In countries endemic for HBV, presentation at a younger age is common and probably related to childhood infection
  • 15. • Unfortunately, in unscreened populations, HCC tends to present at a later stage because of the lack of symptoms in early stages. • Presentation at an advanced stage is often with vague right upper quadrant abdominal pain that sometimes radiates to the right shoulder. • Nonspecific symptoms of advanced malignancy such as anorexia, nausea, lethargy, and weight loss are also common
  • 16. • Another common presentation of HCC is hepatic decompensation in a patient with known mild cirrhosis or even in patients with unrecognized cirrhosis. • HCC can rarely present as a rupture, with the sudden onset of abdominal pain followed by hypovolemic shock secondary to intraperitoneal bleeding
  • 17. diagnosis • Diagnosis is often confirmed with a biopsy Diagnosis can sometimes be confirmed with blood or imaging tests • Physical examination • Blood test for alpha-fetoprotein (AFP); 50%-70% of people with primary liver cancer have elevated levels • Ultrasound of the abdomen Computed tomography (CT or CAT) scan • Magnetic resonance imaging (MRI)
  • 18. • AFP measurements can be helpful in the diagnosis of HCC. An AFP level higher than 20 ng/mL is noted in approximately 75% of documented cases of HCC.
  • 19. • Radiologic investigation is a critical part of the diagnosis of HCC. Ultrasound plays a significant role in screening and early detection of HCC, but definitive diagnosis and treatment planning rely on CT and/or MRI. • Contrast-enhanced CT and MRI protocols aimed at diagnosing HCC take advantage of the hypervascularity of these tumors, and arterial phase images are critical to assess the extent of disease adequately
  • 20. • CT and MRI also evaluate the extent of disease in terms of peritoneal metastases, nodal metastases, and extent of vascular and biliary involvement. • Detection of bland or tumor thrombus in the portal or hepatic venous system is also important and can be diagnosed with any of these modalities.
  • 21. • If atypical features appear on imaging, a biopsy should be obtained for histologic diagnosis. • For hepatic nodules larger than 2 cm, a triplephase CT or MRI scan is required if typical features of HCC are identified in combination with an AFP level higher than 200 ng/mL. • If typical features appear on imaging, the diagnosis of HCC is confirmed. • If atypical features are seen, then biopsy is required to confirm the histologic diagnosis.
  • 22. TNM GRADING • T1 :solitory tumour 2cm without vascular invasion T1a : Solitary tumor <2 cm T1b :Solitary tumor >2 cm without vascular invasion T2 :Solitary tumor >2 cm with vascular invasion; or multiple tumors, none <5 cm • T3: Multiple tumors, at least one of which is >5 cm • T4 :Single tumor or tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum
  • 23. Regional lymph nodes (N) NX:Regional lymph nodes cannot be assessed • N0: No regional lymph node metastasis • N1: Regional lymph node metastasiS • METASTASIS • Mo :NO distant metastasis • M1:Distant Metastasis
  • 24. treatment • 1.Resection of right and left lobe :Hemipectotomy • 2.Trans arterial embolization • 3.Partiation of liver • 4.liver transplantation: we follow Millams criteria a)size of tumor <5cm b) multiple tumor size <3cm and no. 2-3 c) no extrahepatic or vascular spread
  • 25. CHOLANGIOCARCINOMA • Malignancy of bile duct epithelium • Usually in older patients
  • 26. TYPES OF CHOLANGIOCARCINOMA • INTRA HEPATIC - those starting within the liver • PRE HEPATIC – Bile duct cancer starting in the hilum • DISTSAL BILE DUCT CANCER – those satrting from down.
  • 27. RISK FACTOR • Primary cholangitis • Ulcerative colitis • Cirrohsis • HBV,HCV,HIV toxins • Diabetes Mellitus MOST COMMON SITE- HILUM- KLASTIN TUMOR • TUMOR MARKERS- CAG-G, CEA
  • 28. HISTOLOGICAL • Diffuse,infiltrate/sclerosinng (worst prognosis) • Nodular/mass forming • Papillary( Best prognosis)
  • 29. CLINICAL FEATURES • Painless progressive jaundice • Fatigue • Anorexia • Clay coloured stools
  • 30. INVESTIGATION • Lab investigation • Tumor markers- CEAX,CA19-9 • USG • CT • MRI + MRCP (ioc)
  • 31. MRI IMAGE OF INTRAHEPATIC CHOLANGIOCARCINOMA • MRI IMAGE OF HILAR CHOLANGIOCARCINOMA
  • 34.
  • 35. TREATMENT • Hilar cholangiocarcinoma: CBD Resection +lymphadenctomy+caudate lobectomy Distal cholangiocarcinoma :Pyrolous sparing Whipples Procedure